Items tagged with Access
1/4/6x24 Mid-campaign report launch webinar - recording now available online (post)
The 1/4/6x24 Campaign and the Stop TB Partnership co-hosted a webinar on 27 March 2024 to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments. The report highlights progress and gaps in scaling up access to shorter, safer TB regimens — one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.
WHO BPaLM Accelerator Platform (post)
The WHO BPaLM Accelerator Platform was established in January 2023, right after the update of the World Health Organization (WHO) guidelines on the treatment of drug-resistant TB in 2022. The purpose of the WHO BPaLM Accelerator Platform is to support countries and stakeholders in information exchange and technical discussions to address challenges in the adoption and implementation of the BPaLM/BPaL regimen (consisting of bedaquiline, pretomanid, linezolid and moxifloxacin, with the provision of dropping moxifloxacin in case of confirmed resistance to fluoroquinolones). This is also to support the Call to Action on rolling out of the BPaLM regimen and other short regimens for treatment of drug-resistant TB that was initiated by WHO and its multiple partners.
New partnership to improve access to new antibiotics in low- and middle-income countries to boost efforts to combat TB and AMR (post)
The Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership’s Global Drug Facility (GDF) announced a partnership agreement to improve global access to antibiotics. GDF will incorporate GARDP’s portfolio of antibiotics to improve appropriate and affordable antibiotic access for the benefit of patients and health systems, particularly in low- and middle-income countries.
South Africa: Slow progress after decision to make TB prevention pills more widely available (post)
Besides preventing illness and death, TB preventive treatment (TPT) is estimated to be highly cost-effective. Yet, uptake of TPT is not what it could be in South Africa. Tiyese Jeranji asks how much has changed since the Department of Health last year decided to make TPT much more widely available.
Global Fund and Unitaid increase collaboration to advance equitable access to health products (post)
Geneva, 27 June 2024 – The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and Unitaid signed a new collaboration framework to advance equitable access to high-quality and affordable health products and innovations in low- and middle-income countries over the next three years.
Critics blast ‘inward, technocratic’ MSF leadership for closing Access Campaign (post)
The leadership of Médecins sans Frontières (MSF) is under significant global pressure to reverse its decision to close its Access Campaign.
Johnson & Johnson agrees to lower price of TB drug bedaquiline, allow production in South Africa (post)
South Africa's anti-trust regulator announced on July 5 that drugmaker Johnson & Johnson (J&J) and its subsidiary, Janssen Pharmaceutical, have agreed to withdraw a secondary patent on the tuberculosis (TB) drug bedaquiline.
Johnson & Johnson's patent for paediatric TB drug rejected in India, move hailed as 'significant victory' for children (post)
New Delhi: In a big victory for TB activism and children suffering from TB in India, the country’s patent office rejected Johnson & Johnson’s (J&J) patent application for the paediatric formulation of Bedaquiline on Friday, July 5.
Consensus statement: The inclusion of children and adolescents in TB diagnostic development and evaluation (post)
Using an online Delphi process, stakeholders from academia, industry, government, funding agencies, and advocacy achieved consensus on an approach to include children and adolescents in TB diagnostic tool development and evaluation.
Better, shorter TB treatments are available. Why aren’t more people receiving them? (post)
TB activists co-founded the 1/4/6×24 Campaign to demand the universal implementation of shorter and more effective TB regimens: as little as one month or once weekly for TB prevention, four months for drug-sensitive TB, and six months for drug-resistant TB by the end of 2024.
Page 52 of 83 · Total posts: 0
←First 51 52 53 Last→